Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease

[1]  I. Módy,et al.  Amyloid β induces interneuron-specific changes in the hippocampus of APPNL-F mice , 2020, PloS one.

[2]  H. Nishimaru,et al.  Astaxanthin Ameliorated Parvalbumin-Positive Neuron Deficits and Alzheimer’s Disease-Related Pathological Progression in the Hippocampus of AppNL-G-F/NL-G-F Mice , 2020, Frontiers in Pharmacology.

[3]  R. J. McDonald,et al.  Age-dependent behavioral and biochemical characterization of single APP knock-in mouse (APPNL-G-F/NL-G-F) model of Alzheimer's disease , 2019, Neurobiology of Aging.

[4]  I. Vertkin,et al.  Secreted amyloid-β precursor protein functions as a GABABR1a ligand to modulate synaptic transmission , 2019, Science.

[5]  R. D'Hooge,et al.  Subtle behavioral changes and increased prefrontal-hippocampal network synchronicity in APPNL−G−F mice before prominent plaque deposition , 2017, Behavioural Brain Research.

[6]  M. Whittington,et al.  Insoluble Aβ overexpression in an App knock-in mouse model alters microstructure and gamma oscillations in the prefrontal cortex, and social and anxiety-related behaviours , 2018, bioRxiv.

[7]  R. D'Hooge,et al.  Increased Insoluble Amyloid-β Induces Negligible Cognitive Deficits in Old AppNL/NL Knock-In Mice , 2018, Journal of Alzheimer's disease : JAD.

[8]  T. Saido,et al.  Neuroinflammation in mouse models of Alzheimer's disease , 2018, Clinical & experimental neuroimmunology.

[9]  Jürgen Götz,et al.  Rodent models for Alzheimer disease , 2018, Nature Reviews Neuroscience.

[10]  T. Saido,et al.  Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis , 2018, BMC Neuroscience.

[11]  K. Fukunaga,et al.  The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice , 2018, Neuroscience.

[12]  R. D'Hooge,et al.  Spatial reversal learning defect coincides with hypersynchronous telencephalic BOLD functional connectivity in APPNL-F/NL-F knock-in mice , 2018, Scientific Reports.

[13]  T. Saido,et al.  Reduction in open field activity in the absence of memory deficits in the App NL−G−F knock-in mouse model of Alzheimer’s disease , 2018, Behavioural Brain Research.

[14]  Hui Zheng,et al.  Practical considerations for choosing a mouse model of Alzheimer’s disease , 2017, Molecular Neurodegeneration.

[15]  B. Winblad,et al.  APP mouse models for Alzheimer's disease preclinical studies , 2017, The EMBO journal.

[16]  Y. Louzoun,et al.  Corrigendum to “Unraveling cognitive traits using the Morris water maze unbiased strategy classification (MUST-C) algorithm” [Brain Behav. Immun. 52C (2016) 132–144] , 2017, Brain, Behavior, and Immunity.

[17]  S. Itohara,et al.  Cognitive deficits in single App knock-in mouse models , 2016, Neurobiology of Learning and Memory.

[18]  Tomer Illouz,et al.  Unraveling cognitive traits using the Morris water maze unbiased strategy classification (MUST-C) algorithm , 2016, Brain, Behavior, and Immunity.

[19]  R. J. McDonald,et al.  Barriers to developing a valid rodent model of Alzheimer's disease: from behavioral analysis to etiological mechanisms , 2015, Front. Neurosci..

[20]  A. Palmeri,et al.  Rodent models for Alzheimer’s disease drug discovery , 2015, Expert opinion on drug discovery.

[21]  Rebecca Burwell,et al.  Severity of spatial learning impairment in aging: Development of a learning index for performance in the Morris water maze. , 1993, Behavioral neuroscience.

[22]  R. Hammer,et al.  Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow , 2014, Molecular Neurodegeneration.

[23]  S. Itohara,et al.  Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.

[24]  F. Schmitt,et al.  Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models , 2014, Front. Genet..

[25]  M. Savić,et al.  Midazolam impairs acquisition and retrieval, but not consolidation of reference memory in the Morris water maze , 2013, Behavioural Brain Research.

[26]  Robert Lalonde,et al.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD) , 2012, Neuroscience & Biobehavioral Reviews.

[27]  F. LaFerla,et al.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. , 2012, Current pharmaceutical design.

[28]  Gianluigi Forloni,et al.  APP Transgenic Mice: Their Use and Limitations , 2011, NeuroMolecular Medicine.

[29]  Paul W. Frankland,et al.  Frontiers in Integrative Neuroscience Integrative Neuroscience , 2022 .

[30]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[31]  Hartwig Wolburg,et al.  Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology , 2006, EMBO reports.

[32]  H. Schröder,et al.  Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels , 2005, Neurobiology of Disease.

[33]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[34]  D. Borchelt,et al.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.

[35]  B. Strooper,et al.  FAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction , 2002, Neurobiology of Aging.

[36]  B. de Strooper,et al.  FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. , 2002, Neurobiology of aging.

[37]  D. Flood,et al.  Presenilin-1 P264L Knock-In Mutation: Differential Effects on Aβ Production, Amyloid Deposition, and Neuronal Vulnerability , 2000, The Journal of Neuroscience.

[38]  Miles W. Miller,et al.  Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice , 1999, Nature Medicine.

[39]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[41]  B. Greenberg,et al.  Enhanced Amyloidogenic Processing of the β-Amyloid Precursor Protein in Gene-targeted Mice Bearing the Swedish Familial Alzheimer's Disease Mutations and a “Humanized” Aβ Sequence* , 1996, The Journal of Biological Chemistry.

[42]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[43]  M. Gallagher,et al.  Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. , 1993, Behavioral neuroscience.